Williams-Jones, Bryn
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Bryn Williams-Jones
Williams-Jones, Bryn, 1972-
VIAF ID: 107204662 (Personal)
Permalink: http://viaf.org/viaf/107204662
Preferred Forms
-
100 0 _
‡a
Bryn Williams-Jones
-
100 1 _ ‡a Williams-Jones, Bryn
-
100 1 _
‡a
Williams-Jones, Bryn
-
100 1 _ ‡a Williams-Jones, Bryn
-
100 1 _
‡a
Williams-Jones, Bryn
-
100 1 _
‡a
Williams-Jones, Bryn
-
100 1 _ ‡a Williams-Jones, Bryn, ‡d 1972-
4xx's: Alternate Name Forms (7)
5xx's: Related Names (1)
- 510 2 _
‡a
Université de Montréal
Works
| Title | Sources |
|---|---|
| Are Military and Medical Ethics Necessarily Incompatible? A Canadian Case Study |
|
| Assessment of a multimedia-based prospective method to support public deliberations on health technology design: participant survey findings and qualitative insights |
|
| Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector |
|
| Asymmetry in scientific method and limits to cross-disciplinary dialogue: toward a shared language and science policy in pharmacogenomics and human disease genetics |
|
| Authorship and responsibility in health sciences research: a review of procedures for fairly allocating authorship in multi-author studies |
|
| ‘Be ready against cancer, now’: direct-to-consumer advertising for genetic testing |
|
| Between Policy and Politics: When Bioethics Ventures into Public Debate |
|
| Beyond a pejorative understanding of conflict of interest |
|
| Biopolitical Barriers to a Potterian Bioethics: The (Potentially) Missed Opportunity of Epigenetics. |
|
| Book Review: Who Owns Life? |
|
| Can bioethics save biotechnology? |
|
| Challenges for Corporate Ethics in Marketing Genetic Tests |
|
| Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs? |
|
| Combat Hospital's deployment of ethics and entertainment |
|
| The commercialization of genetic research, 1999: |
|
| Conceptualising Ethical Issues in the Conduct of Research: Results from a Critical and Systematic Literature Review |
|
| Conflicts of interest and the (in)dependence of experts advising government on immunization policies |
|
| Conflicts of interest policies for authors, peer reviewers, and editors of bioethics journals |
|
| Consent is not enough--putting incompetent patients first in clinical trials. |
|
| Containing Global Antibiotic Resistance: Ethical Drug Promotion in the Developing World |
|
| Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness? |
|
| COVID-19 and Moral Imperialism in Multinational Clinical Research |
|
| Democracy unleashed--unpacking the tooth fairy in drug industry R&D. |
|
| Democratising access to genetic services. |
|
| Développement d’un cours francophone en ligne sur les politiques publiques en santé : une collaboration internationale |
|
| Drug Familiarization and Therapeutic Misconception Via Direct-to-Consumer Information |
|
| Dupras and Williams-Jones Respond |
|
| Embodiment, property, and the patenting of human genetic material. |
|
| Epigenetics and the environment in bioethics |
|
| Ethical Challenges for Patient Access to Physical Therapy: Views of Staff Members from Three Publicly-Funded Outpatient Physical Therapy Departments |
|
| Ethical health technology assessment in Latin America: lessons from Canada and Argentina |
|
| Ethical issues raised by private practice physiotherapy are more diverse than first meets the eye: recommendations from a literature review |
|
| Ethics and genetics: susceptibility testing in the workplace |
|
| Ethics education in public health: where are we now and where are we going? |
|
| The expert and the lay public: reflections on influenza A (H1N1) and the risk society. |
|
| Global bioethics -- myth or reality? |
|
| The Global HLA Banking of Embryonic Stem Cells Requires Further Scientific Justification |
|
| Global pharmacogenomics: where is the research taking us? |
|
| Governing 'dual-use' research in Canada: A policy review |
|
| Health care professionals and bedbugs: an ethical analysis of a resurgent scourge |
|
| High-throughput electronic biology: mining information for drug discovery |
|
| History of a gene patent: tracing the development and application of commercial BRCA testing |
|
| How do business model and health technology design influence each other? Insights from a longitudinal case study of three academic spin-offs |
|
| How do medical device manufacturers' websites frame the value of health innovation? An empirical ethics analysis of five Canadian innovations |
|
| Imagining Truly Open Access Bioethics: From Dreams to Reality |
|
| Informal PrEP: an emerging need for nomenclature |
|
| Knowledge commons or economic engine--what's a university for? |
|
| Legalistic or Inspirational? Comparing University Conflict of Interest Policies |
|
| Low Back Pain: Investigation of Biases in Outpatient Canadian Physical Therapy |
|
| Managing conflicts of interest should begin with dialogue and education, not punitive measures: comment on "Toward a sociology of conflict of interest in medical research" by Sarah Winch and Michael Sinnott |
|
| Mapping the integration of social and ethical issues in health technology assessment |
|
| Mapping translational research in personalized therapeutics: from molecular markers to health policy |
|
| Misconduct and Misbehavior Related to Authorship Disagreements in Collaborative Science |
|
| Narrative Symposium: Political Influence on Bioethical Deliberation |
|
| Open Innovation in Drug Discovery. |
|
| Operationalizing wait lists: Strategies and experiences in three hospital outpatient physiotherapy departments in Montreal |
|
| Pharmacogenetics: the bioethical problem of DNA investment banking |
|
| Pharmacogenomic technologies: a necessary "luxury" for better global public health? |
|
| Precompetitive activity to address the biological data needs of drug discovery |
|
| Preparing for the arrival of "pink Viagra": strengthening Canadian direct-to-consumer information regulations |
|
| Principles for Incorporating Farmers in the Ethical Assessment of Genetically Modified Crops |
|
| Private genetic testing in Canada: a summary |
|
| Promoting research on research integrity in Canada |
|
| Protecting public health or commercial interests? The importance of transparency during immunization campaigns |
|
| Regulating Direct-to-Consumer Drug Information: A Case Study of Eli Lilly’s Canadian 40over40 Erectile Dysfunction Campaign |
|
| REPRODUCTIVE TOURISM IN ARGENTINA: CLINIC ACCREDITATION AND ITS IMPLICATIONS FOR CONSUMERS, HEALTH PROFESSIONALS AND POLICY MAKERS |
|
| Researchers' Perceptions of Ethical Authorship Distribution in Collaborative Research Teams |
|
| Rhetoric and hype: where's the 'ethics' in pharmacogenomics? |
|
| La santé publique : stratégies d'influence et acceptabilité sociale |
|
| Scientific competency questions as the basis for semantically enriched open pharmacological space development |
|
| Shifting emphasis from pharmacogenomics to theragnostics |
|
| Should we perform kidney transplants on foreign nationals? |
|
| Social contract theory and just decision making: lessons from genetic testing for the BRCA mutations |
|
| Stem cell research ethics: consensus statement on emerging issues |
|
| Supervisor-student relations: examining the spectrum of conflicts of interest in bioscience laboratories |
|
| Technologies of the self in public health: insights from public deliberations on cognitive and behavioural enhancement |
|
| Toward interoperable bioscience data |
|
| Towards an Integration of PrEP into a Safe Sex Ethics Framework for Men Who Have Sex with Men |
|
| Validation d'un questionnaire auto-administré sur les valeurs en politique publique de santé |
|
| What leads to better health care innovation? Arguments for an integrated policy-oriented research agenda |
|
| What place for ethics? An overview of ethics teaching in occupational therapy and physiotherapy programs in Canada |
|
| Where There’s a Web, There’s a Way: Commercial Genetic Testing and the Internet |
|
| Who should travel in kidney exchange programs: the donor, or the organ? |
|
| The worlds and modalities of engagement of design participants: A qualitative case study of three medical innovations |
|
